GeoVax Labs (GOVX) Accumulated Expenses (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Accumulated Expenses of $724670.0 for Q2 2026, up 3.66% year-over-year from $699076.0 in Q2 2025, and down 17.91% quarter-over-quarter from $882816.0 in Q4 2025.
GeoVax Labs (GOVX) Accumulated Expenses (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Accumulated Expenses for 17 consecutive years, with $724670.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Accumulated Expenses rose 3.66% year-over-year to $724670.0; the TTM figure through Jun 2026 stood at $724670.0 (up 3.66% YoY), while the FY2025 annual figure was $882816.0, down 29.8% from the prior year.
- Accumulated Expenses eased to $724670.0 in Q2 2026 per GOVX's latest filing, from $882816.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.7 million in Q3 2022 and bottomed at $460220.0 in Q3 2024.
- Historically, Accumulated Expenses has averaged $1.9 million across 5 years, with a median of $1.4 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 8296.36% — and 2024, when it sank 83.96%.
- GeoVax Labs' Accumulated Expenses stood at $3.0 million in 2022, then slumped by 76.1% to $716931.0 in 2023, then surged by 75.41% to $1.3 million in 2024, then declined by 29.8% to $882816.0 in 2025, then slipped by 17.91% to $724670.0 in 2026.
- Business Quant data shows GOVX's Accumulated Expenses at $724670.0 in Q2 2026, $882816.0 in Q4 2025, and $847766.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 724,670.00 |
| Dec 31, 2025 | 882,816.00 |
| Sep 30, 2025 | 847,766.00 |
| Jun 30, 2025 | 699,076.00 |
| Mar 31, 2025 | 532,292.00 |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 460,220.00 |
| Jun 30, 2024 | 2.28 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 716,931.00 |
| Sep 30, 2023 | 2.87 Mn |
| Jun 30, 2023 | 3.21 Mn |
| Mar 31, 2023 | 3.25 Mn |
| Dec 31, 2022 | 3.00 Mn |
| Sep 30, 2022 | 3.71 Mn |
| Jun 30, 2022 | 3.13 Mn |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 3.38 Mn |
| Sep 30, 2021 | 46,212.00 |
| Jun 30, 2021 | 69,342.00 |